The KD Pharma Group has acquired the manufacturing assets of the former Rohner. The assets give KD access to complementary technologies to further expand its pharmaceutical CDMO business. In addition, the company has strengthened its CDMO team with several key hires from the former Rohner team.
“KD Pharma has all the technology, capacity, and people to become an even larger player in the CDMO market,” said Oscar Groet, CEO of the KD Pharma Group. “Rohner was known for its unique chemical processes and technological capabilities, enabling it to manufacture difficult, multi-step pharmaceutical intermediates and APIs” Groet continued, “this is a natural fit with our strategy to create health solutions and provide value to customers by utilising a unique toolbox of technologies.”
The KD Pharma Group has an existing site in the United Kingdom, as well as a contract softgel manufacturing site in the United States and omega-3 manufacturing sites in Norway and Germany.